Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

I am very excited to hear we are going to be utilizing adaptive trial design for B-OM, this can definitely save time and money.

I am hoping that kevetrin phase 1 trial ends quickly with the next 1 - 3 cohorts, and we also utilize adaptive trial design for phase 2/3.

Ultimate results are still 2 to 3 years away, but I believe within the next year, we can all be confident we have at least one very successful effective drug and possibly 3 drug platforms covering many diseases.

I truly believe the best is yet to come and we are getting closer and closer.